FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174664171> ?p ?o ?g. }

• W3174664171 endingPage "123" @default.
• W3174664171 startingPage "112" @default.
• W3174664171 abstract "Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in phase II and phase III of the belimumab trials was not reflective of the racial distribution observed in the lupus population. This study was undertaken to assess the efficacy and safety of intravenous (IV) belimumab plus standard therapy in patients of self-identified Black race.EMBRACE (GSK Study BEL115471; ClinicalTrials.gov identifier: NCT01632241) was a 52-week multicenter, double-blind, placebo-controlled trial in adults of self-identified Black race with active SLE who received monthly belimumab 10 mg/kg IV, or placebo, plus standard therapy. The optional 26-week open-label extension phase included patients who completed the double-blind phase. The primary end point of the study was SLE Responder Index (SRI) response rate at week 52 with modified proteinuria scoring adapted from the SLE Disease Activity Index 2000 (SLEDAI-2K) (SRI-SLEDAI-2K). Key secondary end points included SRI response rate at week 52, time to first severe SLE flare, and reductions in prednisone dose.The modified intent-to-treat population comprised 448 patients, of whom 96.9% were women and the mean ± SD age was 38.8 ± 11.42 years. The primary end point (improvement in the SRI-SLEDAI-2K response rate at week 52) was not achieved (belimumab 48.7%, placebo 41.6%; odds ratio 1.40 [95% confidence interval 0.93, 2.11], P = 0.1068); however, numerical improvements favoring belimumab were observed, in which the SRI-SLEDAI-2K response rates were higher in those who received belimumab compared with those who received placebo, especially in patients with SLE who had high disease activity or renal manifestations at baseline. The safety profile of belimumab was generally consistent with that observed in previous SLE trials. Adverse events were the primary reasons for double-blind phase withdrawals (belimumab 5.4%, placebo 6.7%).The primary end point of this study was not achieved, but improvement with belimumab versus placebo was observed, suggesting that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry." @default.
• W3174664171 created "2021-07-05" @default.
• W3174664171 creator A5003469260 @default.
• W3174664171 creator A5005565004 @default.
• W3174664171 creator A5007128116 @default.
• W3174664171 creator A5012742212 @default.
• W3174664171 creator A5023279987 @default.
• W3174664171 creator A5025335653 @default.
• W3174664171 creator A5026822726 @default.
• W3174664171 creator A5029461319 @default.
• W3174664171 creator A5034488510 @default.
• W3174664171 creator A5036222488 @default.
• W3174664171 creator A5047601269 @default.
• W3174664171 creator A5048973709 @default.
• W3174664171 creator A5055141120 @default.
• W3174664171 creator A5056200808 @default.
• W3174664171 creator A5069066471 @default.
• W3174664171 creator A5069100301 @default.
• W3174664171 creator A5076651506 @default.
• W3174664171 date "2021-12-09" @default.
• W3174664171 modified "2023-10-16" @default.
• W3174664171 title "Phase <scp>III</scp> / <scp>IV</scp> , Randomized, <scp>Fifty‐Two</scp> –Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus" @default.
• W3174664171 cites W1851080694 @default.
• W3174664171 cites W1972063433 @default.
• W3174664171 cites W1973731651 @default.
• W3174664171 cites W1996276183 @default.
• W3174664171 cites W2044015779 @default.
• W3174664171 cites W2045243474 @default.
• W3174664171 cites W2060208115 @default.
• W3174664171 cites W2093076036 @default.
• W3174664171 cites W2103707875 @default.
• W3174664171 cites W2108696783 @default.
• W3174664171 cites W2110793425 @default.
• W3174664171 cites W2119296184 @default.
• W3174664171 cites W2126846485 @default.
• W3174664171 cites W2131457901 @default.
• W3174664171 cites W2136149088 @default.
• W3174664171 cites W2148749566 @default.
• W3174664171 cites W2297622352 @default.
• W3174664171 cites W2560805062 @default.
• W3174664171 cites W2585480788 @default.
• W3174664171 cites W2624490855 @default.
• W3174664171 cites W2744484065 @default.
• W3174664171 cites W2770877969 @default.
• W3174664171 cites W2773800864 @default.
• W3174664171 cites W2775607224 @default.
• W3174664171 cites W2782542157 @default.
• W3174664171 cites W2801549351 @default.
• W3174664171 cites W2939941674 @default.
• W3174664171 cites W3085025551 @default.
• W3174664171 cites W4236805817 @default.
• W3174664171 cites W4241771140 @default.
• W3174664171 cites W4252124978 @default.
• W3174664171 doi "https://doi.org/10.1002/art.41900" @default.
• W3174664171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34164944" @default.
• W3174664171 hasPublicationYear "2021" @default.
• W3174664171 type Work @default.
• W3174664171 sameAs 3174664171 @default.
• W3174664171 citedByCount "39" @default.
• W3174664171 countsByYear W31746641712021 @default.
• W3174664171 countsByYear W31746641712022 @default.
• W3174664171 countsByYear W31746641712023 @default.
• W3174664171 crossrefType "journal-article" @default.
• W3174664171 hasAuthorship W3174664171A5003469260 @default.
• W3174664171 hasAuthorship W3174664171A5005565004 @default.
• W3174664171 hasAuthorship W3174664171A5007128116 @default.
• W3174664171 hasAuthorship W3174664171A5012742212 @default.
• W3174664171 hasAuthorship W3174664171A5023279987 @default.
• W3174664171 hasAuthorship W3174664171A5025335653 @default.
• W3174664171 hasAuthorship W3174664171A5026822726 @default.
• W3174664171 hasAuthorship W3174664171A5029461319 @default.
• W3174664171 hasAuthorship W3174664171A5034488510 @default.
• W3174664171 hasAuthorship W3174664171A5036222488 @default.
• W3174664171 hasAuthorship W3174664171A5047601269 @default.
• W3174664171 hasAuthorship W3174664171A5048973709 @default.
• W3174664171 hasAuthorship W3174664171A5055141120 @default.
• W3174664171 hasAuthorship W3174664171A5056200808 @default.
• W3174664171 hasAuthorship W3174664171A5069066471 @default.
• W3174664171 hasAuthorship W3174664171A5069100301 @default.
• W3174664171 hasAuthorship W3174664171A5076651506 @default.
• W3174664171 hasBestOaLocation W31746641712 @default.
• W3174664171 hasConcept C126322002 @default.
• W3174664171 hasConcept C142724271 @default.
• W3174664171 hasConcept C156957248 @default.
• W3174664171 hasConcept C159654299 @default.
• W3174664171 hasConcept C168563851 @default.
• W3174664171 hasConcept C170286685 @default.
• W3174664171 hasConcept C197934379 @default.
• W3174664171 hasConcept C203014093 @default.
• W3174664171 hasConcept C203092338 @default.
• W3174664171 hasConcept C204787440 @default.
• W3174664171 hasConcept C27081682 @default.
• W3174664171 hasConcept C2775915377 @default.
• W3174664171 hasConcept C2776912625 @default.
• W3174664171 hasConcept C2778453870 @default.
• W3174664171 hasConcept C2778720950 @default.
• W3174664171 hasConcept C2779134260 @default.
• W3174664171 hasConcept C2779561371 @default.

• next